Latest news with #AncaCopaescu
Associated Press
18-03-2025
- Business
- Associated Press
Strategikon Launches VISION 4.4 to Enhance Vendor Management in Clinical Outsourcing
Empowering biopharma and CROs for greater efficiency, control, and compliance SAN FRANCISCO, CA, March 18, 2025 (EZ Newswire) -- Strategikon, a leader in clinical trial outsourcing and vendor management solutions, has announced the launch of VISION 4.4, an advanced upgrade designed to provide biopharma and CROs with greater control, efficiency, and security in clinical trial vendor management. This release introduces enhanced system customization, improved data visualization, and advanced vendor role management, directly addressing key industry challenges such as vendor oversight, trial efficiency, and regulatory compliance. A recent study by the Tufts Center for the Study of Drug Development found that 75% of biopharma professionals cite data inconsistencies, vendor access issues, and inefficient reporting as major obstacles in clinical outsourcing. VISION 4.4 tackles these challenges with three significant enhancements: System & Custom Fields centralizes control over all standard and custom fields, ensuring seamless data consistency across teams. This significantly reduces manual data errors by up to 50%, addressing a key industry pain point where fragmented data across multiple platforms causes delays in decision-making and compliance risks. Configurable Listings & Views improves trial efficiency through personalized dashboards and customizable views. Users can filter and display only the most relevant vendor data, reducing data retrieval time by 50%. The ability to save preferred views and export reports exactly as displayed eliminates the need for manual adjustments, streamlining vendor oversight and ensuring accurate reporting. Vendor Role Management focuses on security and compliance upgrade that introduces granular permission controls, ensuring vendors can only access the data relevant to their role. Organizations have reported annual losses of up to $3 million due to unauthorized data access, highlighting the need for stronger oversight. VISION 4.4 also includes bulk role management, enabling faster onboarding and reducing security risks associated with manual permissions updates. 'With VISION 4.4, we are delivering what the industry has been demanding—greater control, visibility, and efficiency in vendor management,' said Anca Copaescu, CEO of Strategikon. 'By integrating AI-powered customization, advanced reporting, and enhanced security features, we are empowering biopharma teams to make faster, data-driven decisions while ensuring compliance and operational excellence.' Strategikon invites industry professionals to experience VISION 4.4 in action: Strategikon is dedicated to reducing costs and accelerating the market readiness of medical innovations through tailored, cloud-based solutions for clinical trial planning, outsourcing, and vendor management. Our flagship platforms, Clinical Maestro® and VISION®, replace antiquated manual processes with streamlined, end-to-end management tools designed to enhance operational efficiency while mitigating regulatory risks. For more information, visit ### SOURCE: Strategikon
Associated Press
31-01-2025
- Business
- Associated Press
Strategikon Partners with Sira Sight.AI to Revolutionize Global Clinical Trial Cost Benchmarking
Collaboration expands Clinical Maestro budgeting capabilities to provide total cost benchmarking for both service and site costs SAN FRANCISCO, CA, January 31, 2025 (EZ Newswire) -- Strategikon, a leading provider of advanced clinical business solutions, today announced a strategic partnership with Sira a pioneer in AI-driven site cost intelligence. This collaboration aims to integrate global investigator grant data with Strategikon's Clinical Maestro® PORTOFOLIO, creating a comprehensive and cutting-edge platform for clinical trial cost benchmarking. Strategikon and Sira Sight plan to deliver these integrated capabilities in the second half of 2025. Site costs, which typically represent 20% to 60% of total trial costs, are a critical component of clinical development. Ensuring Fair Market Value (FMV) in site budgets is essential to comply with global regulations and maintain ethical standards. However, the industry faces challenges with outdated and geographically limited data sources for FMV, resulting in elongated negotiations, delayed study start-up and increased trial costs. 'Integrating reliable site cost benchmark data with Clinical Maestro PORTOFOLIO, our advanced service cost prediction engine, represents a major step forward in bringing transparency to the total cost of executing a clinical trial,' said Anca Copaescu, CEO of Strategikon. 'The partnership with Sira Sight leverages AI and sophisticated predictive models to deliver an integrated solution, further solidifying Clinical Maestro's position as the market leader in global clinical cost benchmarking.' Eric Gildenhuys, CEO of Sira Sight, added, 'Sira Sight brings the power of Artificial Intelligence to the acquisition, transformation, and harmonization of site budget data at global scale. By collaborating with investigator sites, CROs, and biopharmaceutical companies, we are delivering the next generation site cost negotiation marketplace and reliable FMV data, addressing one of the industry's major bottlenecks—site contract negotiation. The collaboration with Strategikon brings two major data sources, site and service cost under a unified umbrella.' Mark Weinstein, Chairman of the Strategikon Board of Directors, expressed enthusiasm about the partnership: 'Strategikon's solutions are transforming and modernizing clinical business operations. Expanding our PORTOFOLIO offering with investigator cost intelligence is a strategic investment that will drive significant value for our clients.' About Strategikon Strategikon's mission is to lower the cost and expedite the time-to-market of new medical treatments through purpose-built, cloud-based solutions that enhance clinical trial planning, outsourcing, and vendor compliance. Its flagship solutions, Clinical Maestro® and VISION, replace manual processes and outdated procurement tools with modern, end-to-end outsourcing management platforms, while reducing regulatory risk associated with vendor oversight. For more information, visit About Sira Sira is the pharmaceutical industry's first AI-driven site budget negotiation marketplace. By working with clinical research sites, CROs, and pharmaceutical companies, Sira Sight aims to deliver site cost intelligence at global scale to provide reliable Fair Market Value (FMV) and a comprehensive Clinical Trial Agreement (CTA) negotiation toolset. 617-899-0986 SOURCE: Strategikon
Associated Press
28-01-2025
- Business
- Associated Press
Strategikon and Danforth Advisors Collaborate to Maximize Efficiencies in Clinical Business Operations
SAN FRANCISCO, CA, January 28, 2025 (EZ Newswire) -- Strategikon, a leader in advanced clinical trial business solutions, has announced a strategic alliance with Danforth Advisors, leading provider of integrated business, clinical and commercial support services for life science companies. This partnership is set to accelerate long-term customer value by combining Danforth's domain consulting expertise with Strategikon's innovative software solutions, including Clinical Maestro® and VISION, creating a seamless approach to clinical business transformation. 'The collaboration between domain consultants and software solution providers is paramount for driving sustainable value, breaking resistance to change, and ensuring long-term adoption of new technologies. Our ongoing work with Danforth Advisors in process improvement, change management, and clinical outsourcing has already shown significant results in these areas,' said Anca Copaescu, the CEO of Strategikon. 'Danforth is committed to delivering maximum value for clients, and that includes the adoption of cutting-edge technologies to increase efficiency in the supplier selection, negotiation, contract and relationship management processes that are critical to outsourced drug development,' said Rene Stephens, Managing Director of Danforth's Clinical Business Operations practice. 'This collaboration expands the reach and impact of our team's expertise, helping sponsor companies navigate the development path with confidence and efficiency.' About Strategikon Strategikon is dedicated to reducing costs and accelerating the market readiness of medical innovations through tailored, cloud-based solutions for clinical trial planning, outsourcing, and vendor management. Its flagship platforms, Clinical Maestro® and VISION, replace antiquated manual processes with streamlined, end-to-end management tools designed to enhance operational efficiency while mitigating regulatory risks. For more information, visit About Danforth Advisors Danforth is the life science industry's trusted partner for strategic and operational support across business, clinical, and commercial functions. The company advises and executes in the areas of finance and accounting, strategic communications, human resources, risk management, clinical and regulatory, market research, and commercial readiness and launch. Founded in 2011, Danforth has partnered with more than 1,500 life science companies, private and public, across all stages of the corporate lifecycle. The company serves clients around the globe from its base in Waltham, Massachusetts and regional operations in New York, Pennsylvania, New Jersey, Maryland, California, and London. Additional information is available at SOURCE: Strategikon
